The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment discontinuation due to toxicity for patients with acute myeloid leukemia (AML) treated on SWOG S1203.
 
Suravi Raychaudhuri
Stock and Other Ownership Interests - BioNTech SE; Moderna Therapeutics; Pfizer
 
Megan Othus
Consulting or Advisory Role - Biosight; Cascadia Labs; Daiichi Sankyo; Glycomimetics; Merck
Other Relationship - Celgene; Glycomimetics; Grifols
 
Mary-Elizabeth M. Percival
Consulting or Advisory Role - Genentech
Research Funding - Abbvie (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); Biosight (Inst); Cardiff Biotechnology (Inst); Celgene/Bristol-Myers Squibb (Inst); Glycomimetics (Inst); Immunogen (Inst); Oscotec; Pfizer (Inst); Telios (Inst)
 
Guillermo Garcia-Manero
Honoraria - Abbvie; Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb/Celgene; Curis; Genentech; Gilead Sciences; Novartis
Consulting or Advisory Role - Acceleron Pharma; Astex Pharmaceuticals; Bristol-Myers Squibb
Research Funding - Abbvie; Aprea Therapeutics; Astex Pharmaceuticals; Bristol-Myers Squibb; Curis; Genentech; Gilead Sciences; Novartis
 
Frederick R. Appelbaum
Stock and Other Ownership Interests - Jasper Therapeutics
 
Harry Paul Erba
Consulting or Advisory Role - Abbvie/Genentech; Agios; Amgen; Astellas Pharma; Bristol-Myers Squibb/Celgene; Celgene; Daiichi Sankyo; Glycomimetics; Immunogen; Incyte; Janssen Oncology; Jazz Pharmaceuticals; Kura Oncology; Macrogenics; Novartis; Pfizer; Sumitomo Dainippon Pharma Oncology; Takeda; Trillium Therapeutics
Speakers' Bureau - Abbvie; Agios; Bristol Myers Squibb Foundation; Incyte; Jazz Pharmaceuticals; Novartis; SERVIER
Research Funding - Abbvie (Inst); Abbvie (Inst); Agios (Inst); ALX Oncology (Inst); Amgen (Inst); Aptose Biosciences (Inst); Daiichi Sankyo (Inst); FORMA Therapeutics (Inst); Gilead/Forty Seven (Inst); Glycomimetics (Inst); Immunogen (Inst); Jazz Pharmaceuticals (Inst); Macrogenics (Inst); Novartis (Inst); PTC Therapeutics (Inst); SERVIER; Sumitomo Dainippon Pharma Oncology (Inst)
Other Relationship - Bristol-Myers Squibb/Celgene; Celgene; Glycomimetics
(OPTIONAL) Uncompensated Relationships - Daiichi Sankyo
 
Jacob Appelbaum
Employment - Fred Hutch Cancer Center
Consulting or Advisory Role - Incyte
Research Funding - 2seventy bio
(OPTIONAL) Uncompensated Relationships - 2seventy bio